1.Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB, Traxler P. (1996) Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors, 6 (11):[10.1016/0960-894X(96)00197-7]
2.Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. (1997) Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives, 7 (2):[10.1016/S0960-894X(96)00601-4]
3.Mahboobi S, Sellmer A, Eswayah A, Elz S, Uecker A, Böhmer FD.. (2008) Inhibition of PDGFR tyrosine kinase activity by a series of novel N-(3-(4-(pyridin-3-yl)-1H-imidazol-2-ylamino)phenyl)amides: a SAR study on the bioisosterism of pyrimidine and imidazole., 43 (7):[PMID:17983688][10.1016/j.ejmech.2007.09.021]
4.Cui J, Fu R, Zhou LH, Chen SP, Li GW, Qian SX, Liu S.. (2013) BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives., 23 (8):[PMID:23473682][10.1016/j.bmcl.2013.01.113]
5.Sun W,Netzer WJ,Sinha A,Gindinova K,Chang E,Sinha SC. (2019) Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins., 62 (6):[PMID:30873837][10.1021/acs.jmedchem.8b02007]
